Anti-tumor activity of cabozantinib by FAK down-regulation in human oral squamous cell carcinoma
Cabozantinib is a tyrosine kinase inhibitor involved in inhibition of cell proliferation and colony formation. We studied anti-cancer properties of cabozantinib in oral squamous cell carcinoma cells. The viability of BHY and HSC-3 cells decreased with increase in cabozantinib concentration and time....
Saved in:
Main Authors: | Da-Lu Li (Author), Zhu-Liang Wei (Author), Wen-Mei Zhang (Author), Zhi-Gang Li (Author) |
---|---|
Format: | Book |
Published: |
Bangladesh Pharmacological Society,
2015-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling
by: Qingzong Si, et al.
Published: (2021) -
A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
by: Yuhua Wei, et al.
Published: (2022) -
Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022) -
Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)
by: Jie Chen, et al.
Published: (2021) -
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
by: Emeline Colomba, et al.
Published: (2022)